CHINA GLASS (03300) plans to issue convertible bonds to Hillhouse Capital Group with a principal amount of approximately 1.5 billion yuan.
China Glass (03300) announced that on March 30, 2026, the company entered into a non-legally binding memorandum of understanding with Hony Capital Group Limited (a potential subscriber). The potential subscriber (or its affiliates) will subscribe to approximately RMB 1.5 billion convertible bonds, which can be converted into ordinary shares of the company.
China Glass (03300) announced that on March 30, 2026, the company entered into a non-binding memorandum of understanding with Hony Capital Group Limited (the potential subscriber). The potential subscriber (or its affiliates) will subscribe to approximately RMB 1.5 billion in principal amount of convertible bonds, which can be converted into common shares of the company.
The board of directors believes that raising funds through the proposed issuance of convertible bonds will provide timely funds for the group to refinance existing debts and partially repay them, thereby alleviating immediate debt repayment pressure and reducing overall financial burden. These arrangements will strengthen the group's capital structure and liquidity position, supporting its sustainable business operations and development.
Related Articles

China Glass (03300) announced a net loss attributable to equity shareholders of approximately RMB 4.893 billion in 2025, representing an increase of about 4.58 times year-on-year.

CITIC SEC: The value of energy security is highlighted, and public utilities are expected to benefit from reevaluation

SSY GROUP(02005): Upatinib has been approved by the China Food and Drug Administration for registration as an active pharmaceutical ingredient for use in marketed preparations.
China Glass (03300) announced a net loss attributable to equity shareholders of approximately RMB 4.893 billion in 2025, representing an increase of about 4.58 times year-on-year.

CITIC SEC: The value of energy security is highlighted, and public utilities are expected to benefit from reevaluation

SSY GROUP(02005): Upatinib has been approved by the China Food and Drug Administration for registration as an active pharmaceutical ingredient for use in marketed preparations.

RECOMMEND

Chinese Innovative Drug Assets Attract Major Foreign Acquisition, Cooperation Models Diversify
26/03/2026

Four Giants Subscribe As Memory Manufacturer Confirms TWD 78.718 Billion Private Placement For Capacity Expansion
26/03/2026

Year‑On‑Year Surge Exceeding 500%: Hong Kong IPOs Top HKD 100 Billion This Year
26/03/2026


